



## A protecting group-free synthesis of deazathiamine: A step toward inhibitor design

Hong Zhao<sup>a</sup>, Luiz Pedro S. de Carvalho<sup>b</sup>, Carl Nathan<sup>b</sup>, Ouathek Ouerfelli<sup>a,\*</sup>

<sup>a</sup>Organic Synthesis Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, PO Box 237, New York, NY 10065, United States

<sup>b</sup>Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10065, United States

### ARTICLE INFO

#### Article history:

Received 18 August 2010

Revised 7 September 2010

Accepted 10 September 2010

Available online 16 September 2010

#### Keywords:

Deazathiamine

3-Deazathiaminediphosphate

3-Deazathiamine

3-Deazathiamine synthesis

2,3,5-Tribromo-3-methylthiophene

### ABSTRACT

The discovery of 3-deazathiamine diphosphate (deazaThDP) as a potent inhibitor analog of the cofactor thiamine diphosphate (ThDP) has highlighted the need for an efficient and scalable synthesis of deazaThDP. Such a method would facilitate development of analogs with the ability to inhibit individual ThDP-dependent enzymes selectively. Toward the goal of developing selective inhibitors of the mycobacterial enzyme 2-hydroxy-3-oxoadipate synthase (HOAS), we report an improved synthesis of deazaThDP without use of protecting groups. Tribromo-3-methylthiophene served as a versatile starting material whose selective functionalization permitted access to deazaThDP in five steps, with potential to make other analogs accessible in substantial amounts.

© 2010 Elsevier Ltd. All rights reserved.

The emergence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains of *Mycobacterium tuberculosis* poses a global threat.<sup>1,2</sup> New anti-infectives are needed to combat tuberculosis and other infectious diseases that are becoming resistant to the current arsenal of drugs. An estimated one-third of the global population is infected with *M. tuberculosis*. Although most hosts do not develop active disease, tuberculosis kills almost two million people worldwide every year.<sup>3</sup> *M. tuberculosis* adapts its metabolism to survive under adverse conditions in the host, such as nutrient deprivation, hypoxia, acidification and oxidative stress.<sup>4</sup> One approach to finding new anti-infectives against tuberculosis is to design inhibitors that target biochemical pathways used by the pathogen to survive in the host.

It was recently demonstrated that *M. tuberculosis* organizes a tricarboxylic acid (TCA) cycle that lacks the  $\alpha$ -ketoglutarate dehydrogenase complex (KDH).<sup>5</sup> The TCA cycle is an essential pathway used by aerobic organisms to metabolize carbohydrates, amino acids, and fatty acids to produce energy, reducing power and biosynthetic precursors. In the canonical TCA cycle, KDH carries out decarboxylation of  $\alpha$ -ketoglutarate, producing succinyl-CoA, which is then converted to succinate. Lack of KDH activity is a TCA cycle variant common among anaerobic bacteria and microaerophiles.<sup>6</sup> It was initially proposed that the *M. tuberculosis* enzyme Rv1248c converts  $\alpha$ -ketoglutarate to succinate via an  $\alpha$ -ketoglutarate

decarboxylase (Kgd)-mediated decarboxylation of  $\alpha$ -ketoglutarate to succinyl semialdehyde (SSA), followed by oxidation of SSA to succinate by a succinyl semialdehyde dehydrogenase, GabD1 or GabD2.<sup>5</sup> Recent studies demonstrated that production of SSA is too slow to support this as a means for joining the oxidative and reductive branches of the TCA cycle. Instead, Rv1248c couples the decarboxylation of  $\alpha$ -ketoglutarate to carbonylation with glyoxylate, forming 2-hydroxy-3-oxoadipate (HOA), which spontaneously decarboxylates to 5-hydroxylevulinate. Thus, Rv1248c has been re-named HOA synthase (HOAS).<sup>7</sup>

The HOAS reaction in *M. tuberculosis* is strictly dependent upon ThDP (**1**) (Fig. 1).<sup>7</sup> ThDP is an enzyme cofactor in a broad range of biosynthetic pathways and reactions, usually involving the cleavage and formation of C–C bonds adjacent to a carbonyl group.<sup>8,9</sup> Humans cannot synthesize thiamine, thus making it an essential vitamin, whereas in bacteria, ThDP biosynthesis is regulated by riboswitches, metabolite-sensing domains found in messenger RNAs (mRNAs) of metabolite-synthesis proteins.<sup>10</sup> The ThDP riboswitch detects ThDP




Figure 1. Structures of thiamine diphosphate and 3-deazathiamine diphosphate.

\* Corresponding author. Tel.: +1 212 639 7771; fax: +1 212 717 3654.

E-mail address: [o-ouarfelli@ski.mskcc.org](mailto:o-ouarfelli@ski.mskcc.org) (O. Ouerfelli).

with 1000-fold higher affinity than thiamine monophosphate or thiamine.<sup>11</sup> Ligand-binding to the ThDP riboswitch promotes a conformational change in the mRNA that leads to termination of transcription and/or inhibition of translation.<sup>11–14</sup> When intracellular ThDP concentrations are in excess, the expression of related metabolite-synthesis proteins is repressed, and the repression is relieved when availability of metabolite falls below threshold.<sup>10</sup> Because HOAS is predicted to be essential for survival of *M. tuberculosis* during infection<sup>15</sup> and depends on ThDP, and because it appears that humans possess neither HOAS nor riboswitches, ThDP analogs selective for HOAS or selective for riboswitches might block survival of *M. tuberculosis* in infected individuals.


Many ThDP analogs have been chemically synthesized<sup>16</sup> and used to explore the biophysical significance of ThDP functional groups by serving as probes for spectroscopic and mechanistic studies. They have also been applied as putative transition or intermediate state analogs in protein crystallography.<sup>9,16</sup> Some ThDP analogs are effective inhibitors of ThDP-dependent enzymes<sup>16</sup> and riboswitches.<sup>13,16,17</sup> DeazaThDP (**2**) is a ThDP analogue in which the N-3 atom of ThDP is replaced by a carbon, converting the charged thiazolium ring to a neutral thiophene. The absence of a positive charge at the 3-position prevents formation of the reactive ylid required for catalysis.<sup>16</sup> Another result of this modification is that deazaThDP binds to target enzyme with greater affinity and speed than the natural coenzyme<sup>16,18</sup> despite maintaining the size and steric profile of ThDP. Studies of *Zymomonas mobilis* pyruvate decarboxylase and the *Escherichia coli* KDH E1 subunit suggest that deazaThDP binds these enzymes 25,000- and 500-times more tightly than ThDP, respectively.<sup>18</sup>

Given the established utility of deazaThDP as a tool to understand ThDP biochemistry, as well as its potential value as a precursor to development of an anti-infective targeting HOAS in *M. tuberculosis*, we sought to improve the efficiency and scalability of deazaThDP and deazaThDP syntheses as further outlined below. We have developed a concise and general synthetic route to deazaThDP. This report is a formal synthesis of deazaThDP since the transformation of the former to the latter has been described previously<sup>18,19</sup> and worked in our hands.

Previously reported syntheses<sup>20,21</sup> require amongst other things the construction of the thiophene ring itself. With a view toward a scalable synthesis, we reasoned to start with the readily available 2,3,5-tribromo-4-methylthiophene. We hoped to take advantage of different reactivities of the three bromine atoms in 2,3,5-tribromo-4-methylthiophene **3** to instill a sequence of alkylating events that may, in principle, be conducted in one pot, and allow installation of desired functional groups in a predictable order. The three bromine atoms rank in reactivity from most reactive, Br-2, to the least reactive, Br-3. A wealth of possible transformations could be applied to construct thiophene-based chemical libraries. For example, Br-2 could be exchanged for a proton or metal-exchanged (umpolung) to react with an electrophile. Alternatively, these could also be substituted directly or through transition-metal catalyzed couplings to provide further diversity. These examples give a glimpse of the versatility of such a starting material.<sup>22</sup>

The retro-synthetic analysis profile of deazaThDP is as follows (Scheme 1). The pyrimidine ring should form easily from condensation of a cyanimine such as intermediate **7** and acetamide. In turn, the cyanimine would result from reacting 3-anilinopropionitrile with aldehyde **6**. The latter would be the result of an orchestrated sequence of transformations starting with halogen-proton exchange at Br-2, followed by metallation at position 5 and alkylation of ethylene oxide, and lastly, another metal-halogen exchange at Br-3, and treatment of the resulting anion with DMF.

For the synthesis at hand, Br-2 in 2,3,5-tribromo-4-methylthiophene was reductively cleaved with zinc powder in refluxing acetic




Scheme 1. Retrosynthetic analysis profile of 3-deazaThDP.

acid<sup>22a,23</sup> (Scheme 2) to give dibromide **4**, which set the stage for the reaction of the next reactive bromide, Br-5. This was selectively transmetalated and the resulting anion was condensed with ethylene oxide to introduce the hydroxyethyl side chain of **5** in good yield.

The structure of compound **5** was further confirmed by an NOE experiment (Table 1) and exhaustive lithiation, followed by quenching with water to ensure that regiochemistry occurred as intended, which was the case (Scheme 3). For instance, the methyl group showed a strong NOE with the two methylene groups on the side chain, but had no interaction with the aromatic proton at C2, providing additional proof of regiochemistry as drawn. Treatment of compound **5** with excess of *n*-butyllithium followed by quenching with water gave thiophene **9**, which was easily recognized through the characteristic NMR signature which showed two aromatic hydrogens appearing as expected as two coupled doublets.

The remaining bromine in **5** was transmetalated with *n*-butyllithium to give the corresponding lithiated intermediate, which was reacted with DMF to produce aldehyde **6** in 64% isolated yield.<sup>24,25</sup> Compound **6** thus obtained displayed proton and <sup>13</sup>C NMR spectra identical to the described values.<sup>20</sup> Finally, formation of the pyrimidine ring was accomplished in two steps.<sup>19,26</sup> The aldehyde was condensed with β-anilinopropionitrile to give α,β-unsaturated nitrile **7**, as a *Z* isomer. Base-catalyzed heterocyclization with acetamide proceeded smoothly in refluxing ethanol to afford the desired deazathiamine **8**.



As a preliminary indication of anti-infective potential, we tested the enzyme inhibitory activity of compound **8** in vitro (Fig. 2). DeazaThDP and deazaThDP inhibited HOAS-catalyzed reduction of ferricyanide (Fig. 2) with IC<sub>50</sub> values of 144 ± 11 μM (*n*<sup>H</sup> = 0.91 ± 0.05)



Scheme 2. Synthesis of 3-deazathiamine. Reagents and conditions: (a) Zn powder, AcOH, reflux overnight; (b) *n*-BuLi, 1.0 equiv, ethylene oxide, BF<sub>3</sub>·Et<sub>2</sub>O, −78–0 °C, 3 h; (c) *n*-BuLi, 2.0 equiv, DMF, −78 °C to rt, 3 h; (d) β-anilinopropionitrile, NaOMe/MeOH, DMSO, 40 °C, 2 h; (e) acetamide hydrochloride, NaOEt/EtOH, reflux, 48 h.

**Table 1**  
NOE data of **5**

Irradiated peaks (ppm)	Enhanced peaks (ppm)
3.03	3.83, 2.17
2.17	3.83, 3.03

**Scheme 3.** NOE and exhaustive lithiation of **5**.**Figure 2.** Inhibition curves for deazaTh and deazaThDP. Experiments were performed in phosphate buffer pH 7.4 at 37 °C. DeazaTh (closed circles) was varied from 30 to 600 μM and deazaThDP (open circles) was varied from 1 to 200 μM. Symbols represent data and the solid curve represents the fit to  $v = v_0/[1 + (I/IC_{50})^{nH}]$ .

and  $6.7 \pm 0.8 \mu\text{M}$  ( $n^H = 1.28 \pm 0.14$ ), respectively. Correction for the competitive nature of the inhibition and concentration of TDP allowed estimation of inhibition constants  $K_i^{\text{calcd}}_{\text{deazaTh}} = 76 \mu\text{M}$  and  $K_i^{\text{calcd}}_{\text{deazaThDP}} = 3.5 \mu\text{M}$ .

In summary, we have completed an efficient synthesis of deazaThDP. Readily available 2,3,5-tribromo-4-methyl thiophene allowed us to avoid construction of the thiophene ring, which greatly shortened the synthesis. To date, this five-step synthesis appears to be the most concise among reported routes. Metallations of the bromide allow for considerable flexibility, since it has been demonstrated that more than one electrophile couples with the lithiated intermediate. The ease of the C2 carbon modification, the active site in catalysis, offered by this method has the potential to provide general access to many deazaThDP analogs and to thiophene derivatives as well.

As with other ThDP-dependent enzymes, substitution of the nitrogen from the thiazolium ring of thiamine by a carbon leads to the generation of a good mimic of neutral or zwitterionic intermediates, which exist along the reaction pathway of ThDP-dependent enzymes. Some of these intermediates display greater affinity for these enzymes than ThDP itself. DeazaTh, which lacks the diphosphate portion of the cofactor, binds HOAS with affinity similar to ThDP, and deazaThDP binds 32-fold more tightly to HOAS

than ThDP. These results indicate that deazaTh analogs are good starting points for rational inhibitor development or as chemical baits for click chemistry or other tethering approaches.

## Acknowledgments

We thank Dr. Samuel J. Danishefsky for critical reading of the manuscript. We also thank Drs. Hartmuth Kolb, Ramulu Poddutoori, and Avdhoot Velankar (UCLA) for early efforts in this project and Professor Tadgh Begley for stimulating discussions. We are grateful for help with analytical data collection as well as interpretation provided by Drs. George Sukenick, Hui Liu, Silvy Ruesli, Ms Hui Fang from the NMR Analytical Core Facility at MSKCC, and Dr. Cliff Soll from the CUNY Mass Spectrometry Facility at Hunter College. The authors also thank Dr. Cynthia Jung for valuable assistance with preparation of the manuscript. This work was supported by NIH grants AL64768(CN) and P30 CA 008748-43 (core grant). The Department of Microbiology and Immunology is supported by the William Randolph Hearst Foundation.

## Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.bmcl.2010.09.053](https://doi.org/10.1016/j.bmcl.2010.09.053).

## References and notes

- Dorman, S. E.; Chaisson, R. E. *Nat. Med.* **2007**, *13*, 295.
- Shenoi, S.; Friedland, G. *Annu. Rev. Med.* **2009**, *60*, 307.
- Barry, C. E., 3rd; Boshoff, H. I.; Dartois, V.; Dick, T.; Ehrt, S.; Flynn, J.; Schnappinger, D.; Wilkinson, R. J.; Young, D. *Nat. Rev. Microbiol.* **2009**, *7*, 845.
- Cook, G. M.; Berney, M.; Gebhard, S.; Heinemann, M.; Cox, R. A.; Danilchanka, O.; Niederweis, M. *Adv. Microbiol. Physiol.* **2009**, *55*, 81–318–319.
- Tian, J.; Bryk, R.; Itoh, M.; Suematsu, M.; Nathan, C. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 10670.
- Guest, J. R. *Philos. Trans. R. Soc. London, Ser. B: Biol. Sci.* **1995**, *350*, 189.
- de Carvalho, L. P.; Zhao, H.; Dickinson, C. E.; Arango, N. M.; Lima, C. D.; Fischer, S. M.; Ouerfelli, O.; Nathan, C.; Rhee, K. Y. *Chem. Biol.* **2010**, *17*, 323.
- Muller, M.; Gocke, D.; Pohl, M. *FEBS J.* **2009**, *276*, 2894.
- Tittmann, K. *FEBS J.* **2009**, *276*, 2893.
- Mandal, M.; Breaker, R. R. *Nat. Rev. Mol. Cell Biol.* **2004**, *5*, 451.
- Winkler, W.; Nahvi, A.; Breaker, R. R. *Nature* **2002**, *419*, 952.
- Thore, S.; Leibundgut, M.; Ban, N. *Science* **2006**, *312*, 1208.
- Serganov, A.; Polonskaia, A.; Phan, A. T.; Breaker, R. R.; Patel, D. J. *Nature* **2006**, *441*, 1167.
- Mironov, A. S.; Gusarov, I.; Rafikov, R.; Lopez, L. E.; Shatalin, K.; Kreneva, R. A.; Perumov, D. A.; Nudler, E. *Cell* **2002**, *111*, 747.
- Sasseti, C. M.; Rubin, E. J. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 12989.
- (a) Agyei-Owusu, K.; Leeper, F. J. *FEBS J.* **2009**, *276*, 2905; (b) Fobare, W. F.; Solvibile, W. R.; Robichaud, A. J.; Malamas, M. S.; Manas, E.; Turner, J.; Hu, Y.; Wagner, E.; Chopra, R.; Cowling, R.; Jin, G.; Bard, J. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 5353.
- Edwards, T. E.; Ferre-D'Amare, A. R. *Structure* **2006**, *14*, 1459.
- Mann, S.; Perez Melero, C.; Hawksley, D.; Leeper, F. J. *Org. Biomol. Chem.* **2004**, *2*, 1732.
- Erixon, K. M.; Dabalos, C. L.; Leeper, F. J. *Chem. Commun. (Camb)* **2007**, 960.
- Hawksley, D.; Griffin, D. A.; Leeper, F. J. *J. Chem. Soc., Perkin Trans. 1* **2001**, 144.
- Thomas, A. A.; De Meese, J.; Le Huerou, Y.; Boyd, S. A.; Romoff, T. T.; Gonzales, S. S.; Gunawardana, I.; Kaplan, T.; Sullivan, F.; Condroski, K.; Lyssikatos, J. P.; Aicher, T. D.; Ballard, J.; Bernat, B.; DeWolf, W.; Han, M.; Lemieux, C.; Smith, D.; Weiler, S.; Wright, S. K.; Vigers, G.; Brandhuber, B. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 509.
- (a) Mitchell, R. H.; Iyer, V. S. *J. Am. Chem. Soc.* **1996**, *118*, 722; (b) Piller, F. M.; Knochel, P. *Org. Lett.* **2009**, *11*, 445; (c) Dapperheld, S.; Feldhues, M.; Litterer, H.; Sisting, F.; Wegener, P. *Synthesis* **1990**, 403.
- Hull, J. W., Jr.; Romer, D. R.; Podhorez, D. E.; Ash, M. L.; Brady, C. H. *Beilstein J. Org. Chem.* **2007**, *3*, 23.
- To insure absence of any regioisomer, we recommend the bidistillation of dibromide **4** and purification of alcohol **5**. Should any regioisomer be present, we have found the desired aldehyde **6** to be chromatographically separable at this stage (please see Supplementary data section).
- Slocum, D. W.; Gierer, P. L. *Chem. Commun.* **1971**, 7, 305.
- Roth, B.; Aig, E.; Rauckman, B. S.; Strelitz, J. Z.; Phillips, A. P.; Ferone, R.; Bushby, S. R.; Sigel, C. W. *J. Med. Chem.* **1981**, *24*, 933.